

arzneimittel



Siltuximab (Sylvant®)

Morbus Castleman » idiopathic multicentric Morbus Castleman

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Andreas Hochhaus

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Siltuximab, idiopathic multicentric Morbus Castleman.....	2
--	----------



Siltuximab (Sylvant®)

Dokument: Fact Sheet

Spezifizierung: Morbus Castleman » idiopathic multicentric Morbus Castleman

Stand: Juli 2022

1 Siltuximab, idiopathic multicentric Morbus Castleman

Siltuximab, idiopathic multicentric Morbus Castleman																																																																																			
		Facts																																																																																	
Parameter	Results ¹⁵	HR ¹⁶	p value																																																																																
RR ²	0 ²¹ vs 34 ²¹		p = 0.0012																																																																																
SAE ⁷	19 vs 23		n.s. ¹⁷																																																																																
TTF ¹⁴	134 ²² vs n.e. ²⁰		p = 0.0084																																																																																
<table border="1"> <tr> <td colspan="2"> Patients </td> <td colspan="2"> Idiopathic multicentric Morbus Castleman </td> </tr> <tr> <td colspan="4"> Trial </td> </tr> <tr> <td>Randomisation</td> <td colspan="3">2 : 1</td> </tr> <tr> <td>N¹</td> <td colspan="3">79</td> </tr> <tr> <td>New Therapy</td> <td colspan="3">Siltuximab</td> </tr> <tr> <td>Control</td> <td colspan="3">Placebo</td> </tr> <tr> <td>Publication</td> <td colspan="3">DOI:10.1016/S1470-2045(14)70319-5</td> </tr> </table>				Patients		Idiopathic multicentric Morbus Castleman		Trial				Randomisation	2 : 1			N ¹	79			New Therapy	Siltuximab			Control	Placebo			Publication	DOI:10.1016/S1470-2045(14)70319-5																																																						
Patients		Idiopathic multicentric Morbus Castleman																																																																																	
Trial																																																																																			
Randomisation	2 : 1																																																																																		
N ¹	79																																																																																		
New Therapy	Siltuximab																																																																																		
Control	Placebo																																																																																		
Publication	DOI:10.1016/S1470-2045(14)70319-5																																																																																		
		Appraisal																																																																																	
																																																																																			
		<table border="1"> <tr> <td colspan="2"></td> <td colspan="2"></td> <td colspan="2"></td> <td colspan="2"></td> <td colspan="2"></td> </tr> <tr> <td>5</td><td>4</td><td>3b</td><td>3a</td><td>2c</td><td>2b</td><td>2a</td><td>1b</td><td>1a</td><td></td> </tr> <tr> <td colspan="10"> Evidence (LoE) </td> </tr> <tr> <td colspan="10"> <table border="1"> <tr> <td>1</td><td>2</td><td>3</td><td>4</td><td>5</td> </tr> <tr> <td colspan="5"> Clinical benefit (ESMO MCBS) </td> </tr> </table> </td> </tr> <tr> <td colspan="10"> ■ curative ■ non-curative </td> </tr> <tr> <td colspan="2"></td> <td colspan="2"> Additional benefit (G-BA) </td> </tr> <tr> <td colspan="2"></td> <td colspan="2"> <table border="1"> <tr> <td>lower</td><td>proven</td><td>not quantifiable</td><td>not minor</td><td>considerable</td><td>major</td> </tr> <tr> <td></td><td></td><td></td><td></td><td></td><td></td> </tr> </table> </td> </tr> </table>												5	4	3b	3a	2c	2b	2a	1b	1a		Evidence (LoE)										<table border="1"> <tr> <td>1</td><td>2</td><td>3</td><td>4</td><td>5</td> </tr> <tr> <td colspan="5"> Clinical benefit (ESMO MCBS) </td> </tr> </table>										1	2	3	4	5	Clinical benefit (ESMO MCBS)					■ curative ■ non-curative												Additional benefit (G-BA)				<table border="1"> <tr> <td>lower</td><td>proven</td><td>not quantifiable</td><td>not minor</td><td>considerable</td><td>major</td> </tr> <tr> <td></td><td></td><td></td><td></td><td></td><td></td> </tr> </table>		lower	proven	not quantifiable	not minor	considerable	major						
5	4	3b	3a	2c	2b	2a	1b	1a																																																																											
Evidence (LoE)																																																																																			
<table border="1"> <tr> <td>1</td><td>2</td><td>3</td><td>4</td><td>5</td> </tr> <tr> <td colspan="5"> Clinical benefit (ESMO MCBS) </td> </tr> </table>										1	2	3	4	5	Clinical benefit (ESMO MCBS)																																																																				
1	2	3	4	5																																																																															
Clinical benefit (ESMO MCBS)																																																																																			
■ curative ■ non-curative																																																																																			
		Additional benefit (G-BA)																																																																																	
		<table border="1"> <tr> <td>lower</td><td>proven</td><td>not quantifiable</td><td>not minor</td><td>considerable</td><td>major</td> </tr> <tr> <td></td><td></td><td></td><td></td><td></td><td></td> </tr> </table>		lower	proven	not quantifiable	not minor	considerable	major																																																																										
lower	proven	not quantifiable	not minor	considerable	major																																																																														

Legende:

¹ N - number of patients

² RR - remission rate, in %

⁷ SAE - serious adverse events, CTCAE grade 3/4

¹⁴ TTF - time to treatment failure

¹⁵ results for control, results for new therapy

¹⁶ hazard ratio for new therapy

¹⁷ n. s. not significant

²⁰ n. e.

²¹ durable tumour and symptomatic response for at least 18 weeks

²² time to treatment failure, in days